FeesSafety
Pluang+

Johnson & Johnson favored over Pfizer for steady growth and dividend in 2027 healthcare sector race

Market News
22 Nov 2026, 20:05 WIB
Erin Kennedy
View Source
Neutral
Johnson & Johnson favored over Pfizer for steady growth and dividend in 2027 healthcare sector race

Johnson & Johnson and Pfizer are key healthcare giants with differing strategies: J&J balances drug innovation and medical devices, while Pfizer focuses on oncology and obesity treatments. J&J reported stronger revenue growth and higher net income, with a stable dividend history exceeding 60 years, making it a more attractive choice for steady investment despite litigation risks. Pfizer, though cheaper and yielding a higher dividend percentage, faces challenges like legal risks and integration of acquisitions, and has underperformed the market over the past decade. Investors seeking stability and long-term growth are advised to consider Johnson & Johnson for 2027 and beyond.

Johnson & Johnson shares are trading at USD 270.47 with a 1.98% dividend yield and a strong 96% buy order activity on Pluang as of Nov 22, 2026 21:01 WIB. Meanwhile, Pfizer is priced at USD 27.40 with a higher dividend yield of 6.28%, but shows a slight 0.51% decline in price and 100% buy order activity. This market data highlights the contrasting investor interest and dividend strategies between the two healthcare giants discussed in the article.

More News (JNJ)

Johnson & Johnson remains a strong dividend stock but trades at a premium valuation.

Johnson & Johnson remains a strong dividend stock but trades at a premium valuation.

Johnson & Johnson continues to show resilience with a 64-year dividend increase streak and raised full-year revenue and earnings guidance for 2026. Despite its strong business fundamentals and leadership in pharmaceuticals and medical devices, the st...

Company Fundamentals
Bullish
34 minutes ago
Johnson & Johnson remains a strong dividend stock but is pricey for value investors now.

Johnson & Johnson remains a strong dividend stock but is pricey for value investors now.

Johnson & Johnson continues to lead in pharmaceuticals and medical devices, boasting a 64-year streak of dividend increases. The company recently raised its full-year revenue and earnings guidance, reflecting solid business performance. However, its ...

Company Fundamentals
Bullish
5 hours ago
Johnson & Johnson favored over Pfizer for steady growth and dividend in 2027 healthcare sector race

Johnson & Johnson favored over Pfizer for steady growth and dividend in 2027 healthcare sector race

Johnson & Johnson and Pfizer, two healthcare giants, are taking different growth paths heading into 2027. Johnson & Johnson maintains a balanced business with strong pharmaceutical and medical device segments, showing steady revenue growth and a soli...

Market News
Neutral
6 hours ago
Dow drops nearly 950 points into correction as tech sell-off spreads and Fed rate hike looms

Dow drops nearly 950 points into correction as tech sell-off spreads and Fed rate hike looms

The Dow Jones Industrial Average fell nearly 950 points on Friday, entering correction territory by closing over 10% below its record high. The sell-off was driven by continued weakness in technology stocks, including a 14% drop in Nvidia after SEC a...

Bearish
9 hours ago
Dividend Aristocrats in Roth IRAs offer tax-free dividends and no required minimum distributions.

Dividend Aristocrats in Roth IRAs offer tax-free dividends and no required minimum distributions.

Dividend Aristocrats are S&P 500 companies with 25+ years of dividend increases, like Coca-Cola, Procter & Gamble, and Johnson & Johnson. Holding them in a Roth IRA shelters dividends from taxes, unlike taxable accounts where dividends face 15% or hi...

Bullish
1 day ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App